New targeted cancer drug tested in patients who ran out of options
Disease control
Terminated
This early-stage study tested a new targeted cancer drug called EO-3021 in adults with advanced stomach and other digestive cancers that had stopped responding to standard treatments. The main goal was to find a safe dose and see if the drug caused tumors to shrink. The study was…
Phase: PHASE1 • Sponsor: Elevation Oncology • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC